Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: Yahoo! Finance
host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business. During the quarter, the company expanded site selection activities for a Phase 3 study of its ARDS (Acute Respiratory Distress Syndrome) drug candidate, EB05 (paridiprubart). Edesa previously secured up to C$23 million from the Canadian government toward the development of EB05, a portion of which is conditionally repayable. The company also intends to evaluate EB05, an anti-TLR4 monoclonal antibody, separately in a broader ARDS population and plans to file an investigational new drug application (IND) for a Phase 2 study in pulmonary fibrosis. "We are positioning our anti-TLR4 respiratory technology for both acute and chronic conditions," said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. "With governments now focusing on host-directed therapeutics as part of their pandemic preparednes
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS [Yahoo! Finance]Yahoo! Finance
- BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDSAccesswire
- Edesa Biotech Reports Fiscal 2nd Quarter 2024 ResultsAccesswire
- Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech to Participate in Bloom Burton Healthcare Investor ConferenceAccesswire
EDSA
Sec Filings
- 6/24/24 - Form 8-K
- 6/4/24 - Form 4
- 6/3/24 - Form SC
- EDSA's page on the SEC website